Upload
n-jones
View
218
Download
3
Embed Size (px)
Citation preview
Evaluation of antigen-specific responses using
in vitro enriched T cells
N. Jonesa, D. Agrawalb, M. Elrefaeia, A. Hansona,V. Novitskyc, J.T. Wongd, Huyen Caoa,*
aCalifornia Department of Health Services, 850 Marina Bay Parkway, VRDL Richmond, CA 94804, USAbPartners AIDS Research Center, Charlestown, MA, USA
cHarvard School of Public Health, Boston, MA, USAdDepartment of Medicine, Massachusetts General Hospital, Boston, MA, USA
Received 25 July 2002; received in revised form 10 October 2002; accepted 4 November 2002
Abstract
Antigen-specific lymphocytes are important in the immune response to viral infection. Peripheral blood mononuclear cells
(PBMC) are traditionally used as a source of effector cells in most immunological studies. We described here the use of the
bispecific monoclonal antibodies (BSMAB) anti CD3:CD8 (CD3,8) and anti CD3:CD4 (CD3,4B) to expand and selectively
enrich CD4+ and CD8+ T cell populations, respectively. The expanded cells demonstrated >90% CD3+CD4+ or CD3 +CD8+
by 14 days. We measured HIV- and CMV-specific responses of these subset-enriched T cell and found that sensitivity and
specificity is similar or higher when compared to PBMC in various cellular immunology assays (CMI). Vbeta analysis of
BSMAB-enriched cells demonstrated comparable repertoire to the parent PBMC. Although both CD45RAhi and CD45ROhi cell
populations were expanded with the BSMAB, selective subset depletion demonstrated that the antigen-specific T cell responses
were restricted to the initial CD45ROhi memory effector subgroup. In conclusion, BSMAB in vitro enrichment of T cells allows
significant expansion of the cell population without loss of specificity. This technique of cell expansion permits studies of T cell
subset function in situations where the initial cell source is scarce, and presents an alternative for viable and functional T cells in
immunological assays.
D 2002 Elsevier Science B.V. All rights reserved.
Keywords: T cell; CMI; Bispecific monoclonal antibody
1. Introduction
T cells play an important role against viral
infection. The recent development of highly sensi-
tive assays to measure T cell responses such as the
ELISpot (Larsson et al., 1999; Altfeld et al., 2000)
and intracellular cytokine flow cytometry (Appay et
al., 2000; Goulder et al., 2000) allows rapid quan-
titation of specific T cell responses directly from
PBMC. However, the detailed examination of virus-
specific T cell response, including epitope mapping
and HLA restriction, still relies heavily on a large
viable source of functional T cells. Cellular immu-
nology assays (CMI) have traditionally utilized
0022-1759/02/$ - see front matter D 2002 Elsevier Science B.V. All rights reserved.
PII: S0022 -1759 (02 )00510 -0
* Corresponding author.
E-mail address: [email protected] (H. Cao).
www.elsevier.com/locate/jim
Journal of Immunological Methods 274 (2003) 139–147
peripheral blood mononuclear cells (PBMC) in
evaluating antigen-specific responses and the quan-
tity and quality of these cells are often limiting.
Furthermore, cryopreservation of PBMC invariably
leads to some degree of decreased cell viability with
the best recovery < 100% (Weingberg et al., 2000),
excluding other factors such as storage and shipping
conditions, and often limits the scope of immuno-
logical studies.
Bispecific monoclonal antibodies (BSMAB) have
two different antigen binding sites, but share a
common Fc region. The CD3,4B BSMAB has both
an anti-CD3 and an anti-CD4 Ag recognition sites,
whereas the CD3,8 BSMAB has both an anti-CD3
and an anti-CD8 Ag recognition sites. When added
to PBMC in the presence of IL2, CD3,4B BSMAB
leads to selective elimination of CD4+ cells, pri-
marily by bridging CD4 molecules on target cells
to the CD3 molecular complexes of CD8+ cells.
Concurrently, CD3,4B activates residual CD3+ (pre-
dominantly CD8+) T cells and results in their rapid
expansion. Similarly, CD3,8 leads to selective cy-
tolysis of CD8+ T cells, and results in rapid pro-
liferation of the residual CD3 + CD4+ T cells
(Wong and Colvin, 1987; Wilson et al., 1995). In
this study, we evaluated cellular immune responses
of BSMAB-expanded T cell population in standard
immunological assays. Our data support the
hypothesis that selective expansion of functional
T cells by BSMAB maintains the antigen-specific
responses and provides a reliable source of viable
cells for in depth analysis of virus-specific T cell
responses.
2. Materials and methods
2.1. Bispecific monoclonal antibody
BSMA CD3,4B and CD3,8 recognize CD3 and
CD4 or CD3 and CD8 antigens, respectively. The
BSMAB are produced by hybrid-hybridomas. The
production of the hybrid-hybridomas and the
BSMAB have been previously described (Wong
and Colvin, 1987; Wong et al., 1989). In brief, the
CD3,8 hybrid-hybridoma was produced by the
fusion of the 12F6 (anti-CD3) and OKT8 (anti-
CD8) hybridomas. It produces the CD3,8 BSMAB
along with a mixture of the parental 12F6, OKT8,
and other hybrid mAb. CD3,8 BSMAB has one CD3
Ag recognition site and one CD8 Ag recognition site
that share a common Fc. The CD3,4B hybrid-
hybridoma was similarly produced by the fusion of
12F6 and Jet4B (anti-CD4) hybridomas. This hybrid-
hybridoma produces the CD3,4B BSMAB along
with a mixture of the parental 12F6 and Jet4B and
other recombinants. The CD3,8 BSMAB and
CD3,4B BSMAB were purified by preparative iso-
electric focusing as previously described. Fractions
that were pure as judged by analytical IEF were
pooled, and their binding properties confirmed by
the staining patterns on peripheral blood lympho-
cytes.
2.2. Cell lines and culture conditions
PBMC from HIV seropositive volunteer donors
from Botswana (SP1) (Novitsky et al., 2001) and
Uganda (SP2, SP3) (Cao et al., 2000) with known
Gag- and Nef-specific responses as well as from CMV
positive healthy HIV seronegative individual (SN1)
were evaluated. Cryopreserved cells were resus-
pended in RPMI 1640 medium containing 10% FCS
at a concentration of 1–2 million per ml with 5 Ag/ml
of CD3,4B or CD3,8 BSMAB. Next day, and sub-
sequently twice a week, the cells were fed with RPMI
1640 media containing 10% FCS and IL-2. The cells
were kept in culture for 10–14 days before being
tested for activity. Cells were sensitized with CMV
lysate (Advanced Biotechnologies, Columbia, MD)
and HIV synthetic peptides (NIH AIDS Research and
Reference Reagent Program, Bethesda, MD) at 1 and
2 Ag/ml, respectively.
2.3. Flow cytometry
2.3.1. Quantifying Vbeta repertoire
The IOTest Beta Mark (Immunotech, Marseille,
France) kit was used for quantitative analysis of the
TCR Vbeta repertoire of T lymphocytes by flow
cytometric analysis. The kit is composed of eight
vials containing mixtures of conjugated TCR Vbeta
antibodies corresponding to 24 different specificities
(about 70% coverage of normal human TCR Vbeta
repertoire). PBMCs or expanded CD8+ cells were
used in the analysis. Tubes were labeled A through
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147140
H with extra tubes used for compensation and as
controls. The cells were incubated at 4 jC for 30
min. They were then washed twice and fixed by
adding 100 Al of 1% paraformaldehyde. Analysis
was done on Becton Dickinson FACScalibur flow
cytometer using the Cell Quest software.
2.3.2. T cell subset study
Depletion of CD45RA+ or CD45RO+ cells was
performed according to manufacturer’s procedures
(Stem Cell Technologies, Canada). Briefly, freshly
isolated PBMC were washed twice with PBS plus
5% FCS (wash buffer). PBMC were resuspended
at 2–5� 107 cells/ml in wash buffer. For depletion
of CD45RA+ cells, 1 ml aliquot of the PBMC
was stained with anti-human CD45A tetramer (3
Ag/ml) for 15 min at room temperature (RT). For
depletion of CD45RO+ cells, 1 ml aliquot of the
PBMC was first stained with biotinylated anti-
human CD45RO (clone UCHL1) for 15 min at
RT. Cells were washed once with wash buffer then
stained with anti-biotin tetrameric antibody (100 Al/
1 ml of cells) for 15 min at RT. Cells were washed
once and resuspended in 1 ml of wash buffer.
Magnetic colloid (60 Al/ml of cells) was added to
stained PBMC from both groups and incubated for
15 min at RT. Depletion was accomplished by bind-
ing of the labeled cells to a 3Wmagnetic column
(Stem Cell Technologies). The percentage of
CD45RA+ or CD45RO+ cells in the depleted ali-
quots was reduced to V 3% as determined by flow
cytometry.
2.3.3. ELISpot
ELISpot assay was performed on cryopreserved
PBMCs and BSMAB-enriched cells generated from
PBMC. Ninety-six-well nitrocellulose plates (Milli-
titer, Millipore, Bedford, MA) were pre-coated over-
night at 4 jC with 0.5 Ag/ml of monoclonal
antibody 1-D1K (Mabtech, Stockholm, Sweden).
The plates were then washed 6X with phosphate-
buffered saline (PBS), and PBMCs were added at
100,000 cells/well in duplicate wells. The CD8 cell
lines were washed twice in RPMI 1640 media and
Fig. 1. (A) PBMC and CD8-enriched cells from an HIV seropositive volunteer was tested for HIV-specific response using overlapping Nef
synthetic pooled peptides (20 amino acids) in the ELISpot assay. (B) Cells from the same individual was tested for activity against CMV
antigens. (C) PBMC and CD8-enriched cells from an HIV seropositive Ugandan volunteer tested against pools of synthetic peptides. All assays
were done with duplicate wells of 100 K/well. Results are reported as spot forming cells (SFC) per million.
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147 141
added at 50,000 cells/well. The plates were incu-
bated overnight at 37 jC in 5% CO2, and biotiny-
lated monoclonal antibody anti-IFN-Mab (Mabtech)
was then added at 0.5 Ag/ml for 100 min followed
by streptavidin-ALP (Mabtech) for 1 h at room
temperature. The plates were washed three times
with PBS and 5-bromo-4-chloro-3-indolyl phos-
phate, and nitro blue (Sigma) was added to develop
the reaction. Tap water was added to stop the
reaction after 15 min. Individual cytokine-producing
cells were detected as dark spots, and subsequently
counted on the ELISpot reader (CTL, Cleveland,
OH). CTL frequency was calculated from the num-
ber of spots (SFC, spot forming cells) subtracted
from the control wells and averaged from the
replicate wells. The final frequency of specific T
cell response was reported as the average frequency
per 106 cells (SFC/million). Responses were consid-
ered positive if the SFCs were at least twice that of
the control and >10 spots per well. Background SFC
was on average less than 10/well.
2.3.4. Chromium release assay
Autologous BLCL infected with recombinant vac-
cinia virus and subsequently inactivated by UV/Psor-
alen were co-cultured with CD8+ enriched cells in the
presence of recombinant IL-2 and tested for activity
within 14 days (Lubaki et al., 1994; Cao et al., 1997).
Target cells were autologous B-LCL infected with
recombinant vaccina virus expressing Gag antigen
and subsequently labeled with radioactive chromium
(51Cr). Effector/target cell ratio (E:T) was 20:1 in a
final volume of 200 Al with all assays performed in
duplicate wells. Supernatant fluid was harvested after
4 h and the percent specific lysis was determined
from the formula: 100� [(experimental release�spontaneous release)/(maximum release�spontane-
ous release)]. HIV-specific CTL activity was defined
Fig. 2. BSMAB enriched CD8+ cells are functional. CD8 cells from a HIV seropositive Ugandan volunteer (SP3) were stimulated with
inactivated autologous BLCL expressing Gag and irradiated feeders and tested for activity after 14 days. (A) Cytolytic activity against Gag was
demonstrated in the standard chromium release assay. (B) ELISpot assay using CD8-enriched cells from the same individual against overlapping
synthetic Gag peptides demonstrated Gag-specific activity against peptide 22. (C) HLA restriction using partially matched BLCL pulsed with
peptide 22 and CD8-expanded T cells demonstrated that the epitope is HLA B14-restricted.
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147142
as 10% above background/control. Spontaneous
release was < 30% of maximal release for all as-
says.
3. Results
3.1. BSMAB-enriched CD8+ cells maintain specific-
ity and functionality
CD8-enriched T cells and PBMCs of HIV sero-
positive individuals (SP1, SP2) were tested for HIV-
specific activity. Expanded CD8+ T cells demon-
strated similar or increased sensitivity and specificity
to HIV antigens when compared to PBMC in the
ELISpot assay (Figs. 1 and 2). In addition, function-
ality as measured by cytolytic activity in the stand-
ard chromium release assay was demonstrated from
CD8-enriched cells from an HIV seropositive indi-
vidual (SP3). CD8+ T cells were stimulated with
autologous BLCL infected with recombinant vacci-
nia viruses expressing HIV antigens that were inac-
tivated with UV/Psoralen as previously described.
Cytolytic activity to Gag was demonstrated for and
corresponded to Gag activity detected by the ELI-
Fig. 3. PBMC from a healthy volunteer with known CD4-mediated
CMV responses as demonstrated by CD4 depletion. PBMC was
depleted for CD45RO and CD45RA and subsequently BSMAB
enriched for CD4+Tcells. Activity against CMV lysate was tested in
the ELISpot assay. CMV-specific response in CD4-enriched cells was
detected in mock depletion and CD45RA-depleted cells but
abrogated with CD45RO depletion. CMV-specific response is
mediated by CD4 +CD45RO T cells. CD4-enriched cells that were
expanded from undepleted, CD45RA or CD45RO depleted PBMC
were tested for CMV-specific activity in the ELISpot assay. Depletion
of CD45RO prior to BSMAB CD4 enrichment resulted in loss of
antigen specific activity, indicating that specific memory phenotype T
cells are expanded. Specific spot forming cells (SFC) were subtracted
over background. Background SFC/million were < 50.
Fig. 4. Quantitative analysis of Vbeta repertoire of PBMC and CD8 enriched T cells were compared using the IOTest Beta Mark kit. No marked
shift in Vbeta expansion was seen in CD8-enriched cells compared to the Vbeta regions from PBMC of a seronegative volunteer.
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147 143
Fig. 5. CD3,8 selective expansion of PBMC results in CD45ROhi phenotype. (A) CD45RA and RO phenotype in PBMC and CD45RA depleted
PBMC. (B) Following addition of BSMAB, the CD4 enriched cells acquired a CD45ROhi phenotype. (C) Depletion of CD45RA followed by
BSMAB expansion demonstrated that the initial CD45ROhi phenotype is maintained with concomitant CCR7-phenotype.
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147144
SPot assay (Fig. 2). The increased yield in expanded
cells allowed for HLA restriction and finer epitope
mapping (Fig. 2).
Similarly, CD4-mediated responses were evaluated
using BSMAB CD3,8 stimulation. CD4-enriched
cells from a CMV-positive healthy volunteer (SN1)
were tested for activity in the ELISpot assay (Fig. 3).
Abrogation of the response after CD4 depletion dem-
onstrated that CMV-specific response is CD4-medi-
ated.
3.2. BSMAB expansion of T cells is polyclonal
Virus-specific activity of CD8-enriched cells was
tested for activity against HIVand CMV in an individ-
ual with known dual responses. Both HIV- and CMV-
specific responses are maintained in the same individ-
ual suggesting that the BSMAB expansion of T cells is
polyclonal (Fig. 1). We also examined the Vbeta
repertoire of PBMC and CD8-expanded cells from
seronegative volunteer SN1. We observed no major
shift in the T cell receptor (TCR) population of the
CD8-enriched T cell and PBMC of seronegative vol-
unteer SN1 (Fig. 4) with similar data obtained from
HIV seropositive individuals (data not shown). To
evaluate whether specific T cell populations were
expanded, we performed CD45RA and CD45RO
depletion of PBMC before BSMAB expansion (Fig.
5).Although the expandedTcells acquired aCD45ROhi
phenotype, only the CD45RA-depleted population
Fig. 6. BSMAB 3,8 addition to PBMC leads to selective enrichment of >90% CD4+ at 14 days by flow cytometry with plots gated on
lymphocyte population. (A) CMV specific response as measured by ELISpot over same period of expansion. Media alone was used as negative
control with responses reported as spot forming cells (SFC)/million cells. CD4+ T cells selected by magnetic bead depletion and expanded with
anti-CD3 was tested for CMV-specific activity in parallel to BSMAB-enriched cells (B).
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147 145
maintained CMV-specificity (Fig. 3), indicating that
antigen-specific T cells are derived from the initial
memory population phenotype of CD45ROhi.
3.3. Kinetics and phenotype bispecific monoclonal
antibody expansion
Addition of BSMSB typically leads to selective
expansion of T cells to >90% after 14 days (range 75–
97%, data not shown). We also evaluated the magnetic
bead depletion method (which required>2M PBMC)
followed by anti CD3 expansion and did not observe
similar expansion kinetic (range 40–65%, data not
shown) with nonspecific activity more significant
(Fig. 6). High level of nonspecific responses is seen
with BSMAB prior to 2 weeks and activity typically
wanes after 4 weeks without restimulation. Pheno-
typic purity of expanded cell population decreases
after 21 days, without restimulation, with concurrent
loss of specific responses (Fig. 6). We found that the
time window for testing BSMAB-enriched T cells is
optimal between 14 and 21 days.
4. Discussion
Detailed analysis of T cell responses is critical in
the understanding of the immunopathogenesis of viral
and other intracellular infections. Recent development
of assays such as the ELISpot and intracellular cyto-
kine flow cytometry, which detect the secretion of
cytokines following antigenic stimulation, has al-
lowed greater sensitivity in the evaluation of anti-
gen-specific T cell response. However, the need for a
viable and functional source of T cells continues to
limit detailed analysis of cellular immune responses.
The addition of bispecific monoclonal antibody to
PBMC results in significant in vitro enrichment and
expansion of the CD8+ and CD4+ T cells. The unique
feature of the BSMAB is that it has only one CD3 Ag
recognition site and one CD4 Ag recognition site that
share a common Fc. Alternative methods that cross-
link anti-CD3 and anti-CD4 or CD8 with anti-CD4
would produce antibody aggregates with two or more
anti-CD3 and anti-CD4 or CD8 binding sites that may
lead to redirected cytolysis of multiple subsets, instead
of predominantly the subset that is targeted by the
specific BSMAB (Wong et al., 1990). BSMAB expan-
sion also offers several major advantages over current
expansion methods such as selective depletion fol-
lowed by anti-CD3 expansion. The technique is
relatively simple (and hence the lower contamination
probability) and does not require extensive purifica-
tion steps with significantly higher yield of cell
subsets. In addition, the method allows investigators
to optimize limited sources of viable PBMC.
We evaluated the functionality of CD4- and CD8-
enriched T cell populations to CMV and HIV in
various immunological assays. We demonstrated that
the sensitivity and specificity of BSMAB expanded T
cells are similar when compared to PBMC using the
standard chromium release assay or the ELISpot and
intracellular cytokine flow cytometry assays. The
polyclonal expansion of T cells, without loss of
specific responses, offers an important tool in the
evaluation of cellular immune response in generating
a source of functional T cells. The expansion of
antigen-specific T cells permits fine mapping of a
response to a protein antigen as well as HLA restric-
tion of a specific response, which typically requires
large quantities of viable PBMC. This technique also
offers the added advantage of known phenotype of
antigen-specific responses (CD8- or CD4-mediated).
The requirement of IL-2 has both advantages and
limitations. It permits the expansion of purified T cell
subsets in the presence of the BSMAB, and enhances
the overall immune reactivity. We noted evidence for
early nonspecific activity that subsided and permitted
assessment of antigen-specific response beyond the
first 10 days of expansion. In this particular study, the
PBMC were selectively stimulated with the CD3,4 or
CD3,8 BSMAB only once and the cell population
gradually loses the immunoactivity after prolonged in
vitro culture condition. BSMAB-expanded T cell
populations were viable for extensive period of time
in artificial capillary cartridges or with restimulation
in previous studies (Liu and Wong, 1999). Without
further assay by subcloning or limiting dilution, the
bulk polyclonal expansion of T cell population pro-
vides qualitative rather than quantitative detection and
analysis of specific responses. Although we found that
both breadth and specificity of responses of these T
cells are comparable to those of PBMC, it is possible
that marginal low frequency responses may not be
favored during the expansion of T cell populations.
We have previously used this technique to assess
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147146
extensive T cell subset function from the limited
source of cryopreserved PBMC in AIDS vaccine trial
(Cao and Al, in press).
In conclusion, we found that bispecific monoclonal
antibody selective enrichment of T cells represents a
simple method of obtaining a large number of T cells
that remain functional after a short period of TCR
stimulation. We demonstrated that this approach has
useful potential and application in the studies of
antigen-specific T cell immunology.
References
Altfeld, M., Trocha, A., Elridge, R., Rosengerg, E.S., Phillips, M.,
Addo, M., Sekaly, R., Kalams, S.A., Burchett, S., McIntosh, K.,
Walker, B.D., Goulder, P.J., 2000. Identification of dominant
optimal HLA B-60 and HLA-B61-restricted cytotoxic T lym-
phocyte epitopes: rapid characterization of CTL responses by
enzyme-linked immunospot assay. J. Virol. 74, 8541–8549.
Appay, V., Nixon, D.F., Donahoe, S.M., Gillespie, M., Dong, T.,
King, A., Ogg, G.S., Speigel, H.M., Conlon, C., Spina, C.A.,
Havlir, D.V., Richmand, D.D., Waters, A., Easterbrook, P.,
McMichael, A.J., Rowland-Jones, S., 2000. HIV-specific
CD8+ T cells produce antiviral cytokines but are impaired in
cytolytic function. J. Exp. Med. 192, 63–75.
Cao, H., Al, E., in press. Immunogenicity to a canarypox HIV
vaccine in seronegative Ugandan volunteers: result of the HIV-
NET 007 vaccine study. J. Infec. Dis.
Cao, H., Kanki, P., Sankale, J.-L., Dieng-Sarr, A., Mazzara, G.P.,
Kalams, S.A., Korber, B., MBoup, S., Walker, B.D., 1997. Cy-
totoxic T-lymphocyte cross-reactivity among different human
immunodeficiency virus type 1 clades: implication for vaccine
development. J. Virol. 71, 8615–8623.
Cao, H., Mani, I., Vincent, R., Mugerwa, R., Mugyenyi, P., Kanki,
P., Ellner, J., Walker, B.D., 2000. Cellular immunity to HIV-1
Clades: relevance to HIV-1 vaccine trials in Uganda. J. Infect.
Dis. 182, 1350–1356.
Goulder, P.J., Tang, Y., Brander, C., Betts, M.R., Altfeld, M., An-
namalai, K., Trocha, A., He, S., Rosengerg, E.S., Ogg, G.,
O’Callaghan, C.A., Kalams, S.A., McKinney, R.E.J., Mayer,
K., Koup, R., Pelton, S.I., MBurchett, S.K., McIntosh, K.,
Walker, B.D., 2000. Functionally inert HIV-specific cytotoxic
T lymphocytes do not play a major role in chronically infected
adults and children. J. Exp. Med. 192, 1819–1832.
Larsson, M., Jin, Z., Ramratnam, B., Ogg, G.S., Engelmayer, J.,
Demoitie, M.-A., McMichael, A.J., Cox, W.I., Steinman, R.M.,
Nixon, D., Bhardwaj, N., 1999. A recombinant vaccinia virus
based ELISPOT assay detects high frequencies of Pol-specific
CD8 T cells in HIV-1-positive individuals. AIDS 13, 767–777.
Liu, Z., Wong, J.T., 1999. Proliferative and regenerative capacities
of CD4+ T cells upton TCR stimulation. Clin. Immunol. 93,
16–23.
Lubaki, M.N., Egan, M.A., Siliciano, R.F., Weinhold, K.J., Bollin-
ger, R.C., 1994. A novel technique for the detection and ex vivo
expansion of HIV type 1-specific cytotoxic T lymphocytes.
AIDS Res. Hum. Retrovir. 10, 1427–1431.
Novitsky, V., Rybak, N., McLane, M.F., Gilbert, P., Chigwedere, P.,
Klein, I., Gaolekwe, S., Chang, S.Y., Peter, T., Thior, I., NDungu,
T., Vannberg, F., Foley, B.T., Marlink, R., Lee, T.H., Essex, M.,
2001. Identification of HIV-1 subtype C Gag-, Tat-, Rev-, and
Nef-specific Elispot-based cytotoxic T-lymphocyte response for
AIDS vaccine design. J. Virol. 75, 9210–9228.
Weingberg, A., Zhang, L., Brown, D., Erice, A., Polsky, B., Hirsch,
M.S., Owens, S., Lamb, K., 2000. Viability and functional ac-
tivity of cryopreserved mononuclear cells. Clin. Diagn. Lab.
Immunol. 7, 714–716.
Wilson, C.C., Wong, J.T., Girard, D., Merril, D.P., Dynan, M., An,
D., Kalams, S.A., Johnson, R.P., Hirsch, M.S., D’Aquila, R.T.,
Walker, B.D., 1995. Ex vivo expansion of CD4+ lymphocytes
from HIV-1 infected persons in the presence of combination
antiretroviral therapy. JID 172, 88–96.
Wong, J.T., Colvin, R.B., 1987. Bi-specific monoclonal antibodies:
selective binding and complement fixation to cells that express
two different surface antigens. J. Immunol. 139, 1369–1374.
Wong, J.T., Pinto, C.E., Gifford, J.D., Kurnick, J.T., Kradin, R.L.,
1989. Characterization of the CD4+ and CD8+ tumor infiltrat-
ing lymphocytes propagated with bispecific monoclonal anti-
bodies. J. Immunol. 143, 3404–3411.
Wong, J.T., Schott, E., Sabga, E.M., Kielpinski, G.G., Colvin, R.B.,
1990. Immunogenic epitopes of the p55 chain of the interleukin
2 (IL2) receptor: relationship to high afficiny IL2 binding and
modulation of the p55 chain. Transplantation 49, 587–596.
N. Jones et al. / Journal of Immunological Methods 274 (2003) 139–147 147